High Purity Moxidectin Powder CAS 113507-06-5: A Comprehensive Guide to its Properties and Applications
Discover the detailed profile of Moxidectin Powder CAS 113507-06-5, a key anthelmintic in animal health.
Get a Quote & SampleProduct Core Value
Moxidectin Powder
Moxidectin Powder, identified by CAS 113507-06-5, is a highly effective anthelmintic drug crucial for controlling parasitic infections in animals. Its purity exceeding 96% and its white crystalline powder form ensure reliable performance in veterinary applications.
- Leverage the power of moxidectin powder CAS 113507-06-5 for superior animal health management.
- Explore the detailed moxidectin chemical properties for informed application in your formulations.
- Source high-quality moxidectin pharmaceutical intermediate, guaranteed by GMP, HSE, ISO 9001, USP, and BP certifications.
- Benefit from the versatility of moxidectin animal husbandry use, covering a wide range of parasitic challenges.
Product Advantages
Exceptional Purity
Ensuring over 96% purity, moxidectin veterinary anthelmintic provides reliable efficacy for parasite control.
Broad Spectrum Efficacy
This white crystalline powder moxidectin is effective against various internal and external parasites, supporting comprehensive animal health.
Certified Quality Assurance
With GMP, HSE, ISO 9001, USP, and BP certifications, you can trust the quality and safety of this moxidectin pharmaceutical intermediate.
Key Applications
Veterinary Medicine
Utilize moxidectin animal husbandry use for treating parasitic infections in livestock and companion animals, promoting optimal health.
Aquaculture Health
Employ moxidectin aquaculture application to safeguard aquatic life from parasitic infestations, ensuring healthier aquatic environments.
Agricultural Use
The moxidectin agriculture use supports crop protection and animal health within the broader agricultural sector.
Pharmaceutical Manufacturing
Integrate this critical moxidectin chemical properties component into various pharmaceutical formulations for enhanced therapeutic outcomes.